Do analysts prefer PMCB or NEUP?

Neuphoria Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 158.30%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is PMCB or NEUP more profitable?

Nuvilex's return on equity of -12.99% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A -12.99% -8.92% Neuphoria Therapeutics N/A -38.31% -28.92%

Do analysts rate PMCB or KYNB?

Kyntra Bio has a consensus price target of $36.80, suggesting a potential upside of 900.00%. Given Kyntra Bio's stronger consensus rating and higher possible upside, analysts plainly believe Kyntra Bio is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kyntra Bio 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43

Which has better earnings and valuation, PMCB or KYNB?

Kyntra Bio has higher revenue and earnings than Nuvilex. Nuvilex is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvilex N/A N/A -$19.42M -$2.31 N/A Kyntra Bio $6.44M 2.31 $183.45M $45.30 0.08

Is PMCB or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Nuvilex's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Nuvilex's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A -12.99% -8.92% Kyntra Bio 2,199.13% N/A -47.27%

Is APLT or PMCB more profitable?

Nuvilex's return on equity of -12.99% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Nuvilex N/A -12.99% -8.92%

Do analysts rate ABOS or PMCB?

Acumen Pharmaceuticals currently has a consensus target price of $1.00, indicating a potential upside of 334.78%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Acumen Pharmaceuticals is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 3 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.71 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ABOS or PMCB?

Nuvilex is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.54 N/A Nuvilex N/A N/A -$19.42M -$2.31 N/A

Is ABOS or PMCB more profitable?

Nuvilex's return on equity of -12.99% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -166.49% -90.79% Nuvilex N/A -12.99% -8.92%

Do analysts prefer PMCB or PLUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, PMCB or PLUR?

Nuvilex has higher earnings, but lower revenue than Pluri. Pluri is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvilex N/A N/A -$19.42M -$2.31 N/A Pluri $1.02M 14.84 -$23.82M -$2.45 N/A

Is PMCB or PLUR more profitable?

Nuvilex has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat Nuvilex's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A -12.99% -8.92% Pluri -2,344.59% N/A -82.71%

Nuvilex (PMCB) Competitors

$0.40 0.00 (-0.77%)

Closing price 03:59 PM Eastern

Extended Trading

$0.41 +0.01 (+1.75%)

As of 06:27 PM Eastern

Compare

PMCB vs. NEUP, KYNB, APLT, ABOS, and PLUR

Should you buy Nuvilex stock or one of its competitors? Nuvilex's main competitors and comparable companies include Neuphoria Therapeutics (NEUP), Kyntra Bio (KYNB), Applied Therapeutics (APLT), Acumen Pharmaceuticals (ABOS), and Pluri (PLUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuvilex compare to Neuphoria Therapeutics?

Nuvilex (NASDAQ:PMCB) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Nuvilex has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Neuphoria Therapeutics has higher revenue and earnings than Nuvilex. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$2.31	N/A
Neuphoria Therapeutics	$1.17M	12.53	-$13.45M	-$6.22	N/A

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 11.0% of Nuvilex shares are held by company insiders. Comparatively, 1.6% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Neuphoria Therapeutics and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.79 beat Neuphoria Therapeutics' score of 0.39 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Very Positive
Neuphoria Therapeutics	Neutral

Nuvilex's return on equity of -12.99% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	-12.99%	-8.92%
Neuphoria Therapeutics	N/A	-38.31%	-28.92%

Neuphoria Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 158.30%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Nuvilex beats Neuphoria Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Nuvilex compare to Kyntra Bio?

Nuvilex (NASDAQ:PMCB) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Nuvilex has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Kyntra Bio has a consensus price target of $36.80, suggesting a potential upside of 900.00%. Given Kyntra Bio's stronger consensus rating and higher possible upside, analysts plainly believe Kyntra Bio is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyntra Bio	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 11.0% of Nuvilex shares are held by company insiders. Comparatively, 4.2% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Kyntra Bio had 1 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Kyntra Bio and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.79 beat Kyntra Bio's score of 0.89 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Very Positive
Kyntra Bio	Positive

Kyntra Bio has higher revenue and earnings than Nuvilex. Nuvilex is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$2.31	N/A
Kyntra Bio	$6.44M	2.31	$183.45M	$45.30	0.08

Kyntra Bio has a net margin of 2,199.13% compared to Nuvilex's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Nuvilex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	-12.99%	-8.92%
Kyntra Bio	2,199.13%	N/A	-47.27%

Summary

Kyntra Bio beats Nuvilex on 12 of the 15 factors compared between the two stocks.

How does Nuvilex compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Nuvilex's return on equity of -12.99% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Nuvilex	N/A	-12.99%	-8.92%

Nuvilex has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Nuvilex	N/A	N/A	-$19.42M	-$2.31	N/A

Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Applied Therapeutics presently has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Nuvilex had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Nuvilex and 0 mentions for Applied Therapeutics. Nuvilex's average media sentiment score of 1.79 beat Applied Therapeutics' score of 0.00 indicating that Nuvilex is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Nuvilex	Very Positive

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 11.0% of Nuvilex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Nuvilex beats Applied Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Nuvilex compare to Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Acumen Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Nuvilex has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

In the previous week, Acumen Pharmaceuticals had 3 more articles in the media than Nuvilex. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.79 beat Acumen Pharmaceuticals' score of -0.20 indicating that Nuvilex is being referred to more favorably in the news media.

Company	Overall Sentiment
Acumen Pharmaceuticals	Neutral
Nuvilex	Very Positive

Nuvilex's return on equity of -12.99% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-166.49%	-90.79%
Nuvilex	N/A	-12.99%	-8.92%

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 11.0% of Nuvilex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Nuvilex is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.54	N/A
Nuvilex	N/A	N/A	-$19.42M	-$2.31	N/A

Acumen Pharmaceuticals currently has a consensus target price of $1.00, indicating a potential upside of 334.78%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Acumen Pharmaceuticals is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.71
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Acumen Pharmaceuticals beats Nuvilex on 7 of the 13 factors compared between the two stocks.

How does Nuvilex compare to Pluri?

Nuvilex (NASDAQ:PMCB) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Pluri had 2 more articles in the media than Nuvilex. MarketBeat recorded 3 mentions for Pluri and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.79 beat Pluri's score of 0.54 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Very Positive
Pluri	Positive

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nuvilex has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Pluri has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Nuvilex has higher earnings, but lower revenue than Pluri. Pluri is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$2.31	N/A
Pluri	$1.02M	14.84	-$23.82M	-$2.45	N/A

Nuvilex has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat Nuvilex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	-12.99%	-8.92%
Pluri	-2,344.59%	N/A	-82.71%

Summary

Nuvilex beats Pluri on 8 of the 12 factors compared between the two stocks.

Get Nuvilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMCB vs. The Competition

Export

Metric	Nuvilex	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.29M	$4.17B	$7.89B	$12.22B
Dividend Yield	N/A	3.64%	2.47%	4.44%
P/E Ratio	-0.17	25.46	35.35	30.86
Price / Sales	N/A	16.28	8.40	5.81
Price / Cash	N/A	26.87	22.22	22.66
Price / Book	0.13	4.21	4.43	3.79
Net Income	-$19.42M	-$22.76M	$3.50B	$390.16M
7 Day Performance	4.72%	-1.08%	-0.97%	-1.10%
1 Month Performance	-1.34%	-6.80%	-4.07%	-6.19%
1 Year Performance	-55.62%	1.72%	2.04%	-5.75%

Nuvilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMCB Nuvilex	1.4652 of 5 stars	$0.40 -0.8%	N/A	-54.3%	$4.29M	N/A	N/A	2	Positive News Gap Down High Trading Volume
NEUP Neuphoria Therapeutics	1.9424 of 5 stars	$2.77 -7.0%	$7.00 +152.7%	-45.1%	$16.13M	$1.17M	N/A	1	Short Interest Increase Gap Up
KYNB Kyntra Bio	3.8255 of 5 stars	$3.66 -7.6%	$36.80 +905.5%	N/A	$16.03M	$4.62M	0.08	34	Analyst Downgrade
APLT Applied Therapeutics	N/A	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
ABOS Acumen Pharmaceuticals	3.054 of 5 stars	$0.21 -1.2%	$1.00 +367.7%	-87.8%	$15.64M	N/A	N/A	61	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMCB) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvilex (PMCB) Competitors

PMCB vs. NEUP, KYNB, APLT, ABOS, and PLUR

How does Nuvilex compare to Neuphoria Therapeutics?

Summary

How does Nuvilex compare to Kyntra Bio?

Summary

How does Nuvilex compare to Applied Therapeutics?

Summary

How does Nuvilex compare to Acumen Pharmaceuticals?

Summary

How does Nuvilex compare to Pluri?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvilex (PMCB) Competitors

PMCB vs. NEUP, KYNB, APLT, ABOS, and PLUR

How does Nuvilex compare to Neuphoria Therapeutics?

Which has more risk and volatility, PMCB or NEUP?

Which has preferable earnings and valuation, PMCB or NEUP?

Do insiders & institutionals have more ownership in PMCB or NEUP?

Does the media refer more to PMCB or NEUP?

Is PMCB or NEUP more profitable?

Do analysts prefer PMCB or NEUP?

Summary

How does Nuvilex compare to Kyntra Bio?

Which has more risk & volatility, PMCB or KYNB?

Do analysts rate PMCB or KYNB?

Do institutionals & insiders have more ownership in PMCB or KYNB?

Does the media refer more to PMCB or KYNB?

Which has better earnings and valuation, PMCB or KYNB?

Is PMCB or KYNB more profitable?

Summary

How does Nuvilex compare to Applied Therapeutics?

Is APLT or PMCB more profitable?

Which has higher earnings and valuation, APLT or PMCB?

Which has more risk and volatility, APLT or PMCB?

Do analysts recommend APLT or PMCB?

Does the media prefer APLT or PMCB?

Do institutionals and insiders have more ownership in APLT or PMCB?

Summary

How does Nuvilex compare to Acumen Pharmaceuticals?

Which has more volatility and risk, ABOS or PMCB?

Does the media refer more to ABOS or PMCB?

Is ABOS or PMCB more profitable?

Do institutionals and insiders hold more shares of ABOS or PMCB?

Which has stronger valuation & earnings, ABOS or PMCB?

Do analysts rate ABOS or PMCB?

Summary

How does Nuvilex compare to Pluri?

Do analysts prefer PMCB or PLUR?

Does the media favor PMCB or PLUR?

Do insiders and institutionals hold more shares of PMCB or PLUR?

Which has more volatility & risk, PMCB or PLUR?

Which has preferable earnings & valuation, PMCB or PLUR?

Is PMCB or PLUR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools